Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.

Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol (2008) 8.85

The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12

The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 5.72

Multiple control of interleukin-8 gene expression. J Leukoc Biol (2002) 5.35

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 4.21

An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol (2008) 3.75

Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol (2007) 3.37

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41

Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27

Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev (2001) 1.97

Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2005) 1.85

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther (2008) 1.81

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene (2003) 1.72

TNF-induced signaling in apoptosis. J Clin Immunol (1999) 1.71

Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol (2000) 1.61

Newcastle disease virus selectively kills human tumor cells. J Surg Res (1992) 1.40

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res (2007) 1.40

An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am J Public Health Nations Health (1952) 1.34

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18

Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol (2009) 1.17

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08

Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol (2010) 1.07

A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med (1998) 1.04

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. Mol Oncol (2011) 1.02

Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother (1994) 0.99

Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther (2009) 0.98

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res (2006) 0.98

Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol (2001) 0.97

Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol (2014) 0.94

A simple in vito cytotoxicity test using the MTT (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric assay: analysis of eugenol toxicity on dental pulp cells (RPC-C2A). Jpn J Pharmacol (1990) 0.94

Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol (2011) 0.92

Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther (2010) 0.88

Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther (2014) 0.88

Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. Cancer Gene Ther (2014) 0.85

Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol (2012) 0.83

A case of human infection with Newcastle disease virus. Southeast Asian J Trop Med Public Health (1976) 0.78

Oncolytic viruses: smart therapeutics for smart cancers. Future Oncol (2012) 0.78

Evaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaques. PLoS One (2013) 0.77